Inimmune
PrivateLast Round
Grant
Feb 1, 2024
Total Funding Raised
$46.58M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Inimmune is a biotechnology company that discovers and develops novel immunotherapeutics and vaccine adjuvants for the treatment of allergy, autoimmunity, infectious diseases, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inimmune Comparables
Compare Inimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adjuvance Technologies | 87% | |
| Access to Advanced Health Institute | 81% | |
| Dynavax Technologies Corporation | 66% |
Inimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 1, 2024 | ||||
| Series A | Jul 9, 2020 | ||||
| Grant | Jul 1, 2020 | ||||
| Grant | Jun 25, 2018 | ||||
| Grant | Feb 14, 2018 |
Key People
Founding team and executive leadership
Inimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Two Bear Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2026
Grew 16% QoQ, from 32 to 37 employees.
- Mar 5, 2026
Ryan McMillian appointed to lead financial strategy.
Inimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Inimmune's valuation, stock price, and market status.
Is Inimmune a public or private company?
Inimmune is a private company.
What is the current stock price of Inimmune?
Inimmune is a private company with no public stock price. No recent secondary market data is available.
How much is Inimmune worth (valuation)?
Valuation information for Inimmune is not publicly available.
Can I buy Inimmune stock?
Inimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Inimmune's last funding round?
Inimmune's most recent funding round was Series A on July 9, 2020.
Who are the main investors in Inimmune?
Key investors in Inimmune include Two Bear Capital.
Will Inimmune IPO soon?
No public IPO plans have been announced for Inimmune.
How can I track Inimmune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Inimmune's secondary market activity and sign up for updates.